• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics
  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
  • USA - English


News provided by

Insilico Medicine

Feb 24, 2021, 09:00 ET

Share this article

Share this article


Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence

HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery — linking together generative chemistry and biology for the first time — to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ("IPF") and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.

Insilico Medicine Documentary: A breakthrough milestone in AI-powered drug discovery reached
Insilico Medicine Documentary: A breakthrough milestone in AI-powered drug discovery reached

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, said:

"The pinnacle of the deep learning revolution can be pinged to 2014 when deep learning systems accelerated by NVIDIA GPUs and AI software started outperforming humans in image recognition and generative adversarial networks were invented. It is also the year when we started the company. In 2016 we demonstrated that a deep learning system can identify a novel biological target from omics data with experimental validation. From 2017 and 2019 we consistently demonstrated that generative AI can invent and design novel molecules that work in human cells and in animals.

But the big question remained —- can AI design a novel molecule for a novel target that has no known inhibitors and has not been validated in a disease? And now we have successfully linked both biology and chemistry and nominated the preclinical candidate for a novel target, with the intention of taking it into human clinical trials, which is orders of magnitude more complex and more risky problem to solve.

To my knowledge this is the first case where AI identified a novel target and designed a preclinical candidate for a very broad disease indication. It is a major milestone for us as our ultimate moonshot is to go after senescence and we need to have many enabling AI technologies that help us understand and manipulate human biology in other chronic diseases."

The company also announced the formation of a team of over 20 expert drug hunters and drug developers in Shanghai led by Dr. Feng Ren, former senior VP of biology and chemistry at Medicilon, and former head of chemistry at GSK, who joined Insilico in February as Chief Science Officer. This team will be responsible for taking the AI-discovered drugs into human clinical trials and creating a broad portfolio of preclinical assets.

Moreover, since Insilico will have the financial resources to go after a limited number of novel targets, the company made its target discovery and generative chemistry systems available to the pharmaceutical and biotechnology companies via its Pharma.AI software suite. PandaOmics target discovery system is available as software as a service and Chemistry42 small molecule generative chemistry platform is available for on-premise deployment since September 2020. So far, the most advanced pharmaceutical companies have started deployments and some deployed Chemistry42. PandaOmics is now used by multiple academic institutions and pharmaceutical companies specializing in novel target discovery.

The preclinical candidate is a first-in-class novel small molecule inhibitor of a novel biological target with unprecedented mechanism of action (MOA). It demonstrated experimentally great in vitro and in vivo efficacy in preclinical studies for idiopathic pulmonary fibrosis, and good safety profile in the 14-day repeated mouse dose range finding study. To nominate a preclinical candidate, Insilico Medicine started with a set of 20 completely novel targets discovered by AI for fibrosis and narrowed down the target to specifically address IPF. Subsequently, Insilico generated a set of novel compounds to selectively inhibit the novel target. The molecules had to be selective, bioavailable, metabolically stable, capable of oral administration, safe, and have many other properties of a good drug. The company also predicted high-probability of success of the phase 2 clinical trial outcome in IPF. The molecules were first generated using Insilico's Chemistry42 system, powered by NVIDIA V100 Tensor Core GPUs, that adopts Structure-based Drug Design (SBDD) generative chemistry approach, tested in human cell and animal models. Subsequently, the molecules were re-designed using the Ligand-based Drug Design (LBDD) to optimize for additional properties, and then tested in human cells and animal models. After a review by a large team of internal and external veteran drug developers specializing in fibrosis, a preclinical candidate was nominated, and IND-enabling experiments started.

From target hypothesis to preclinical candidate selection, Insilico was able to complete target identification, molecule generation and validation through traditional laboratory experiments in less than 18 months and at a total cost of approximately $1,800,000 for IPF and $800,000 for other fibrotic disorders, with less than 80 small molecules synthesized and tested.

Insilico's AI-discovered and validated preclinical candidate for IPF achieves several multiple industry firsts in the fields of biotechnology and drug discovery:

  • By proving the effectiveness of AI-imagined novel drug targets and molecules through successful validation with multiple human cell and animal model experiments, today's breakthrough marks the industry's first-ever scientific validation of AI for R&D leading up to preclinical studies.
  • Linking chemistry and biology for the first time during drug discovery: Historically the steps involved in designing new drugs and validating their effectiveness through preclinical and clinical studies have been disparate parts of the drug discovery process.
  • Insilico has achieved a new record speed and lowest cost for preclinical candidate selection — enabling the dramatic acceleration of preclinical development while drastically decreasing drug development costs by millions of dollars.

"We're rewriting the playbook for drug discovery by being the first mover and leader in creating the first and only AI-powered integrated system for drug discovery," said Dr. Zhavoronkov. "By creating the first universal system linking all of the areas of drug development from target identification, small molecule design, and soon clinical trial outcomes prediction, Insilico's AI platform will be capable of supporting every step of pharmaceutical R&D."

Industry Commentary and Additional Information

"AI is transforming the healthcare industry, enabling breakthroughs that can improve millions of lives. Using NVIDIA's AI platform, Insilico Medicine, a premier NVIDIA Inception member, has done what we only dreamed of a few years ago: applying AI to dramatically accelerate drug discovery. And it is doing so at a time when it's never been more critically important to bring the power of AI to every industry to solve our greatest challenges."  — Jensen Huang, CEO and founder of NVIDIA

"One of the most difficult steps and biggest mysteries in drug discovery is related to target validation, specifically identifying the targets that have a strong impact in a clinical setting. Insilico Medicine has managed to tackle one of the biggest mysteries in drug discovery through its AI endeavors." — Dr. Tudor Oprea, Professor and Chief of the Translational Informatics Division at the University of New Mexico and experienced drug-hunter with 25 years industrial and academic experience in drug discovery

"Speed is everything in drug development. At least 90 percent of the costs associated with getting a drug approved for human use is in the late stage clinical trials. With its AI-powered universal system for drug discovery, Insilico is enabling researchers to figure out how to fail faster much earlier during the many phases of the drug discovery process leading up to clinical trials before it gets too late." — Dr. Charles Cantor, Professor Emeritus at Boston University, member of the Science Advisory Board at Insilico Medicine, co-Founder of Sequenom Inc., and co-Founder of Retrotope Inc. 

"This achievement of Insilico Medicine is another piece of evidence that AI is a powerful tool for drug discovery. By using AI in as many steps of the process as possible, AI can significantly reduce the time and cost to developing effective therapies." — Dr. Alán Aspuru-Guzik, Professor of Chemistry and Computer Science at the University of Toronto, and co-founder of AI companies Kebotix and Zapata Computing

About Insilico Medicine
Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its own pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents. Website http://insilico.com/

SOURCE Insilico Medicine

Related Links

insilicomedicine.com

Modal title

Also from this source

AllianThera Biopharma comes out of stealth and collaborates on AI ...

AllianThera Biopharma comes out of stealth and collaborates on AI ...


Insilico's Chemistry42 AI system integrated into UCB's drug...

Insilico's Chemistry42 AI system integrated into UCB's drug...

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Artificial Intelligence
  • Medical Pharmaceuticals
  • Pharmaceuticals

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.